Can berberine lower cholesterol?

What berberine is and how it affects cholesterol metabolism

In studies, berberine lowers LDL cholesterol by about 15–25% at 500 mg taken two to three times a day, with the effect showing up after 8–12 weeks.

Berberine is an isoquinoline alkaloid extracted from plants such as goldenseal, barberry and Oregon grape. Traditional Chinese and Ayurvedic medicine have used it for centuries, mainly for gastrointestinal infections. One reason it is interesting for cholesterol metabolism is that berberine can activate AMP-activated protein kinase (AMPK), a master regulator of cellular energy metabolism. When AMPK is switched on, the body shifts from storing energy to using it, which has downstream effects on glucose uptake, fat oxidation and lipid synthesis.

Berberine works through several pathways at once:

It stabilizes the mRNA of the LDL receptor, which increases the number of receptors available on liver cells to pull LDL cholesterol out of the bloodstream.
It inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that breaks down LDL receptors, so more receptors stay functional.
It reduces cholesterol synthesis in the liver by downregulating enzymes in the mevalonate pathway, although this effect is modest compared with statins.
It lowers triglycerides through AMPK activation, which increases fatty acid oxidation and reduces new fat production in the liver.

This dual mechanism, raising the number of receptors while preventing their breakdown, is why berberine is sometimes called a “natural PCSK9 inhibitor,” even though it is far less potent than pharmaceutical PCSK9 inhibitors such as evolocumab. The compound’s effect on triglycerides is especially notable in people with metabolic syndrome or type 2 diabetes.

What clinical trials show about berberine and cholesterol

The source article reports an average LDL reduction of 23.8% in a two-month study of 63 patients taking 500 mg of berberine twice daily (described as a 2022 RCT). Whether this matches the linked study still needs to be checked. Combined with 20 mg of simvastatin daily, LDL fell by 31.8% (2022 meta-analysis). The effect is strongest in people with metabolic disorders, who often have high triglycerides alongside insulin resistance. Source Source

The existing studies have limited explanatory power. Most are short, lasting 8 to 16 weeks. Many were done in people with metabolic syndrome or type 2 diabetes rather than in otherwise healthy people with an isolated lipid disorder. Study quality varies: some lack adequate blinding or use small samples. Long-term data on cardiovascular events are still missing. The available studies show changes in lab values. Whether that translates into fewer heart attacks or strokes over decades has not been established.

How berberine lowers LDL and triglycerides at the cellular level

Berberine’s lipid-lowering action starts with AMPK activation. AMPK is a cellular energy sensor that responds to low ATP levels by switching on energy-producing breakdown processes and switching off energy-consuming building processes. When berberine activates AMPK in hepatocytes, it inhibits acetyl-CoA carboxylase, the rate-limiting enzyme in fatty acid synthesis. This reduces the liver’s production of triglycerides and of VLDL particles, the precursors of LDL.

At the receptor level, berberine stabilizes LDL receptor mRNA through a post-transcriptional mechanism that extends the half-life of the mRNA transcript. As a result, more LDL receptors are made and become available on the surface of liver cells. At the same time, berberine suppresses PCSK9 expression at the transcriptional level, reducing the breakdown of existing LDL receptors. The net result is more functional receptors that can clear LDL particles from the bloodstream.

Berberine’s effect on triglycerides is largely mediated by increased fatty acid oxidation in the liver and skeletal muscle. AMPK activation upregulates peroxisome proliferator-activated receptor alpha (PPARα), which promotes the breakdown of fatty acids for energy. This lowers the amount of triglyceride available for packaging into VLDL particles. Berberine also improves insulin sensitivity, which reduces hepatic lipogenesis driven by hyperinsulinemia, a common feature of metabolic syndrome.

The compound’s influence on cholesterol synthesis is less pronounced than that of statins, but still measurable. Berberine downregulates 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), the enzyme statins target, although the degree of inhibition is weaker. This means berberine is not a statin substitute, but it may complement statin therapy by acting through additional pathways.

Which dose, form and timing have been studied?

Dose

The standard dose used in clinical trials is 500 mg two to three times a day, for a total of 1,000–1,500 mg per day (randomized trial from 2023). This schedule reflects berberine’s relatively short half-life of about 5–6 hours, which means blood levels drop quickly after a single dose. Splitting the daily total into several doses keeps plasma concentrations steadier and improves effectiveness. Doses above 2,000 mg per day have been tested, but they do not consistently produce stronger lipid-lowering effects and they raise the risk of gastrointestinal side effects (2023 meta-analysis). Source Source

Supplement form

Berberine has poor oral bioavailability: less than 5% is absorbed from standard formulations. This is due to its low solubility and extensive first-pass metabolism in the liver. Some manufacturers offer liposomal or phytosome formulations meant to improve absorption, although there is only limited clinical evidence that these forms work better (randomized trial from 2023). Berberine hydrochloride is the most studied form and remains the standard. With standard preparations, a large share stays in the gut. Changes in the gut microbiome could therefore contribute to the blood sugar lowering effect. Source

Timing

Berberine should be taken with meals. This improves tolerability by reducing gastrointestinal side effects, and it may improve absorption by slowing gastric emptying. Taking berberine with food also fits its blood sugar lowering effect, since it can blunt post-meal glucose spikes. For twice-daily dosing, the source article suggests breakfast and dinner; for three times daily, lunch as well.

Drug interactions: statins, blood pressure and diabetes medications, anticoagulants and immunosuppressants

Berberine has been studied in combination with statins, and the data point to additive effects on LDL reduction. However, berberine inhibits CYP3A4, the enzyme that metabolizes many statins, including simvastatin and atorvastatin. This can raise statin blood levels and increase the risk of muscle damage. If the two are combined, the treating physician needs to review the statin dose and watch for muscle pain or elevated creatine kinase. Do not reduce the dose on your own. Other drugs with possible interactions:

Blood pressure medications: some are metabolized via CYP3A4, and berberine lowers blood pressure slightly, so the combination can lead to hypotension.
Diabetes medications, especially insulin or sulfonylureas: berberine lowers blood sugar and increases the risk of hypoglycemia.
Immunosuppressants and anticoagulants: some are metabolized via CYP3A4, and berberine inhibits that same pathway.

These combinations require medical supervision.

Who responds best to berberine, and who should be careful?

Berberine’s lipid-lowering effect is most pronounced in people with elevated baseline cholesterol and elevated triglycerides, especially those with metabolic syndrome, prediabetes or type 2 diabetes. The source article names LDL levels above 130 mg/dL or triglycerides above 150 mg/dL as starting values at which a stronger response can be expected. These values are not standalone criteria for a treatment decision. In people with optimal lipid levels, further reductions are unlikely, because berberine’s effect is corrective rather than supraphysiological. Berberine also appears to work better in people with insulin resistance. AMPK activation improves insulin sensitivity, which has downstream effects on lipid metabolism. With elevated fasting insulin or a HOMA-IR score that indicates insulin resistance, berberine could affect both glucose and fat metabolism.

Groups who should be careful include:

Pregnant and breastfeeding women (berberine crosses the placenta and can cause kernicterus, a life-threatening condition in newborns).
People with liver or kidney disease (berberine is metabolized by the liver and excreted by the kidneys, and impaired function can lead to accumulation).
People taking blood pressure or diabetes medications (see the section on interactions).

Gastrointestinal side effects, including cramps, diarrhea and constipation, are common, especially at doses above 1,500 mg per day (2023 meta-analysis). These effects are usually temporary, but they can make regular use harder. Building up the dose gradually may improve tolerability; if you take other medications, agree on this with your doctor. Source

How long does it take for berberine to lower cholesterol?

It takes 8 to 12 weeks for berberine to lower LDL cholesterol. In most studies, the lipid-lowering effect plateaus at that point. Changes in blood lipids are usually not something you can feel. A measurement before starting gives you a baseline; the source article suggests a follow-up test after 8–12 weeks.

Standard lipid panels measure total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Other values can matter for risk assessment. In most labs, LDL cholesterol is a calculated value and can be inaccurate when triglycerides are high. A more precise measure is apolipoprotein B, which reflects the number of artery-damaging lipoprotein particles in the blood, including LDL, VLDL and their remnant particles. ApoB is a better predictor of cardiovascular risk than LDL cholesterol alone.

The source article gives the following values and time frames for follow-up testing:

Marker	Expected change	Follow-up time named in the source article
LDL cholesterol	15–25% decrease in people who respond	8–12 weeks
Triglycerides	15–30% decrease	4–6 weeks
HDL cholesterol	Increase of 2–5 mg/dL, often not clinically significant	8–12 weeks
Lipoprotein(a)	Unchanged, because it is genetically determined	Not affected by berberine
Fasting glucose, HbA1c and fasting insulin	Show metabolic effects beyond lipids	8–12 weeks
High-sensitivity C-reactive protein	May show mild anti-inflammatory effects	8–12 weeks

Look at the full lipid profile before taking it

Putting things in context means looking at the lipid panel and, depending on the question, apolipoprotein B, fasting glucose, the TyG index and inflammatory markers. Lipoprotein(a) reflects a largely genetically determined part of risk that, according to the source article, berberine does not change much. These values help tell different risks apart; on their own, they do not decide whether berberine is suitable.

Frequently asked questions

How does berberine actually lower LDL cholesterol at the cellular level?

Berberine lowers LDL through two complementary mechanisms. First, it stabilizes LDL receptor mRNA in liver cells, extending the mRNA’s half-life and boosting receptor production, so more LDL particles are taken up from the blood. Second, it suppresses PCSK9 at the transcriptional level, reducing the breakdown of existing LDL receptors. Together, these effects increase the net number of functional LDL receptors on hepatocyte surfaces and improve the clearance of cholesterol from the bloodstream.

What is the difference between berberine and a statin for cholesterol control?

Statins work by strongly inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, and can lower LDL cholesterol by 30 to 50 percent. Berberine also downregulates HMG-CoA reductase, but much more weakly. Its main lipid-lowering mechanism is receptor upregulation and PCSK9 inhibition rather than blocking synthesis. Berberine is not a statin substitute; it is a complementary compound that acts through additional pathways and may offer extra benefit in combination with lower statin doses.

How quickly do triglycerides respond to berberine supplementation?

Triglycerides are among the lipid markers that respond fastest to berberine supplementation. Clinical data suggest that people with elevated baseline triglycerides, particularly those with insulin resistance or metabolic syndrome, may see a 15 to 30 percent reduction within 4 to 6 weeks. This quick response reflects berberine’s AMPK-mediated inhibition of new fat production in the liver and its promotion of fatty acid oxidation, which rapidly reduces the liver’s output of triglyceride-rich VLDL particles.

Can berberine be safely combined with a statin?

Berberine has been studied in combination with statins and showed an additive LDL-lowering effect: in one meta-analysis, berberine plus simvastatin lowered LDL cholesterol by 31.8 percent. However, berberine inhibits CYP3A4, the enzyme that metabolizes many statins, which can raise statin blood levels and increase the risk of muscle damage. Combining them requires medical supervision, a review of the statin dose and, where appropriate, checks for muscle pain or elevated creatine kinase. Do not reduce the dose on your own.

What berberine dose is used in clinical trials for lowering lipids?

Clinical trials on lipid lowering have consistently used 500 mg two to three times a day, so 1,000 to 1,500 mg in total per day, taken with meals. This schedule accounts for berberine’s short half-life of about 5 to 6 hours, which causes blood levels to fall quickly after a single dose. Doses above 2,000 mg per day do not produce a meaningfully stronger lipid reduction and make gastrointestinal side effects such as cramps and diarrhea more likely.

Does berberine improve HDL cholesterol as well as LDL?

Berberine does slightly improve HDL cholesterol, but the effect is smaller than its effect on LDL and triglycerides. Clinical studies typically show an HDL increase of 2 to 5 mg/dL, which is statistically significant but not clinically meaningful for most people. Berberine’s main lipid benefits remain lower LDL and lower triglycerides, particularly in people with metabolic syndrome, insulin resistance or type 2 diabetes, where several lipid abnormalities occur at the same time.

In whom has a stronger response been observed?

Berberine produces the largest cholesterol reductions in people with an elevated baseline LDL above 130 mg/dL or triglycerides above 150 mg/dL, especially those with metabolic syndrome, prediabetes or type 2 diabetes. In people with optimal lipid levels, a meaningful further drop is unlikely, because berberine’s effect is corrective rather than supraphysiological. Elevated fasting insulin or a high HOMA-IR score also predict a better lipid response, since improved insulin sensitivity has downstream effects on fat metabolism in the liver.

Does lipoprotein(a) respond to berberine?

Lipoprotein(a) is genetically determined and does not respond much to berberine supplementation. Unlike LDL cholesterol and triglycerides, Lp(a) levels are largely set by the LPA gene, and lifestyle and diet usually change them only a little. Elevated Lp(a) therefore calls for a separate medical risk assessment. The source article names niacin at pharmacological doses and newer RNA-based therapies as approaches under discussion. But lowering the lab value does not automatically mean proven protection against cardiovascular events; the benefits, risks and approval status of these approaches need to be assessed separately.

Sources and references

Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, Chen Q (2021). Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in pharmacology, 12, 653887. https://doi.org/10.3389/fphar.2021.653887 Publication

Ward NC, Reid CM, Watts GF (2022). Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance. Frontiers in cardiovascular medicine, 9, 1060252. https://doi.org/10.3389/fcvm.2022.1060252 Publication

Zamani M, Zarei M, Nikbaf-Shandiz M, Hosseini S, Shiraseb F, Asbaghi O (2022). The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis. Frontiers in nutrition, 9, 1013055. https://doi.org/10.3389/fnut.2022.1013055 Publication

Chen S, Shen W, Liu Y, Dong Q, Shi Y (2023). Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. Chinese medical journal, 136(14), 1690-1698. https://doi.org/10.1097/CM9.0000000000002696 Publication

Li Z, Wang Y, Xu Q, Ma J, Li X, Yan J, Tian Y, Wen Y, Chen T (2023). Berberine and health outcomes: An umbrella review. Phytotherapy research : PTR, 37(5), 2051-2066. https://doi.org/10.1002/ptr.7806 Publication

Di Pierro F, Sultana R, Eusaph AZ, Abrar S, Bugti M, Afridi F, Farooq U, Iqtadar S, Ghauri F, Makhduma S, Nourin S, Kanwal A, Bano A, Bugti AA, Mureed S, Ghazal A, Irshad R, Recchia M, Bertuccioli A, … Khan A (2023). Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial. Frontiers in pharmacology, 14, 1269605. https://doi.org/10.3389/fphar.2023.1269605 Publication